The role of antiandrogen monotherapy in the treatment of prostate cancer

@article{Anderson2003TheRO,
  title={The role of antiandrogen monotherapy in the treatment of prostate cancer},
  author={John Anderson},
  journal={BJU International},
  year={2003},
  volume={91}
}
  • J. Anderson
  • Published 26 February 2003
  • Medicine
  • BJU International
The mainstay of hormonal therapy in prostate cancer has been medical or surgical castration, both of which are associated with loss of libido and impotence, and may not always be acceptable to the patient. Antiandrogen monotherapy is an alternative treatment option to castration. There are two types of antiandrogen, i.e. steroidal (cyproterone acetate, CPA), and nonsteroidal (bicalutamide, flutamide and nilutamide). Data comparing survival outcome with CPA and castration are limited and… Expand
Antiandrogens in the treatment of prostate cancer.
TLDR
In patients with localized disease managed by watchful waiting or in an adjuvant setting, there are no studies showing an advantage in early versus delayed treatment with antiandrogens regarding clinical progression, and antiandrogen monotherapy seems to be an alternative to castration treatment if treatment is required. Expand
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
  • D. Gillatt
  • Medicine
  • Journal of Cancer Research and Clinical Oncology
  • 2006
TLDR
The available evidence indicates that the different antiandrogens should not be regarded as equivalents in clinical practice and so the choice of treatment for patients with prostate cancer should be made on an individual basis. Expand
THE COMPARISON OF THE EFFICACY OF CYPROTERONE ACETATE AND CASTRATION MONOTHERAPIES IN METASTATIC PROSTATE CANCER : A MULTICENTER STUDY OF A TURKISH URO-ONCOLOGY GROUP
Objective: To detect the therapeutic efficacy of CPA and to compare it with surgical or medical castration in advanced prostate cancer Patients and Methods: Patients from 19 Urology Centers withExpand
Androgen deprivation therapy: past, present and future
TLDR
The most extensively studied antagonist, degarelix, avoids the testosterone surge and clinical flare associated with LHRH agonists, offering more rapid PSA and testosterone suppression, improved testosterone control and improved PSA progression‐free survival compared with agonists. Expand
First-Line Hormonal Manipulation: Surgical and Medical Castration with LHRH Agonists and Antagonists, Steroids, and Pure Antiandrogens
TLDR
The gold standard of ADT alone as first-line therapy may well be modified soon thanks to study findings published in 2015 that so far show – at least for patients with metastatic carcinoma of the prostate – statistically significant and clinically relevant advantages of first- line therapy ofADT combined with chemotherapy rather than ADTalone alone. Expand
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
TLDR
Several new analogues displayed improved in vitro activity towards four different prostate cancer cell lines, while maintaining full AR antagonism and therefore representing promising leads for further development, according to a series of molecular modelling studies performed on the AR antagonist conformation. Expand
Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
TLDR
Although the overwhelming majority of prostate cancer patients during treatment of LHRH analogue achieve serum testosterone values within the castration range, individual patients may fail to reach this therapeutic goal, probably more often during treatment with leuprolide acetate than with goserelin acetate. Expand
Hormonal therapy and chemotherapy for advanced prostate cancer
TLDR
Recently reported results of clinical trials have given answers to questions regarding the best therapeutic agents and strategies, and these have broadened the scope of evidence-based therapy in this field. Expand
Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
TLDR
This review assesses the present status of hormonal therapy in metastatic prostate cancer and specifically deals with those aspects of androgen ablation therapy that are still a subject of debate. Expand
Secondary hormonal therapy for advanced prostate cancer.
TLDR
Primary hormonal therapy serves as an excellent therapeutic option in patients with AIPC in whom primary hormonal therapy has failed and Practicing urologists should familiarize themselves with these oral medications, their indications and their potential side effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?
TLDR
Patients with a higher disease burden (PSA >400 ng/ml) may decide that quality of life and symptomatic benefits outweigh the slight survival disadvantage seen in clinical trials and opt for bicalutamide monotherapy as an alternative to castration. Expand
Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer
TLDR
It is not yet clear if antiandrogen are of any benefit in downstaging the extent of disease before prostatectomy and/or radiotherapy, but some evidence exist that pure antiandrogens improve survival if combined with other forms of castration. Expand
Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.
  • Mcleod
  • Medicine
  • The oncologist
  • 1997
TLDR
Bicalutamide appears to have some advantage over flutamide and nilutamide in terms of tolerability, and the reverse is true for hot flashes, which are a side effect of castration. Expand
Nilutamide: An Antiandrogen for the Treatment of Prostate Cancer
TLDR
Nilutamide does not appear to represent a major advance in the treatment of advanced prostate cancer and appears to be somewhat inferior to both flutamide and bicalutamide with regard to adverse effects. Expand
Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
TLDR
The bicalutamide, due to its better tolerability profile, together with its once-daily oral administration regimen, could be considered the antiandrogen of first choice in the treatment of prostatic cancer. Expand
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
PURPOSE Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in whichExpand
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
TLDR
The results indicate that nilutamide as a single agent has an acceptable toxicity and a moderate activity, and may maintain sexual interest in a discrete number of cases, and whether monotherapy with nonsteroidal antiandrogens offers a valid option in the palliation of advanced disease remains to be seen in comparative prospective trials. Expand
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function
TLDR
In the absence of sexual interest, the treatment of sexual dysfunction becomes less relevant and therefore hormonal treatments for advanced prostate cancer which spare sexual interest are needed. Expand
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
TLDR
Bicalutamide monotherapy yielded comparable results relative to standard treatment with MAB, induced fewer side effects, and produced a better QOL. Expand
Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
  • A. Chang, B. Yeap, +8 authors D. Trump
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
As the primary hormonal therapy for stage D2 prostate cancer, DES caused more serious cardiovascular or thromboembolic complications than flutamide, andFlutamide was not as active an initial agent as DES, however, the effectiveness of flutamia in conjunction with other agents compared with DES remains undetermined. Expand
...
1
2
3
4
5
...